Back to today’s briefing

Story perspectives

FDA Approves Johnson & Johnson's Fast-Acting Depression Spray

1/23/2025

40 7

Summary

Story summary

The FDA has granted approval for Johnson & Johnson's Spravato, a groundbreaking nasal spray derived from ketamine, to treat adults battling major depressive disorder who have not found relief from traditional oral antidepressants. This innovative treatment brings renewed hope to the 21 million Americans grappling with depression, promising potential symptom relief in just 24 hours.

1 of 1

Story summary

The FDA has granted approval for Johnson & Johnson's Spravato, a groundbreaking nasal spray derived from ketamine, to treat adults battling major depressive disorder who have not found relief from traditional oral antidepressants. This innovative treatment brings renewed hope to the 21 million Americans grappling with depression, promising potential symptom relief in just 24 hours.